Latest filing published 30 Oct 2025 for 89bio, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Harry H. Mansbach, listed as senior executive, appears in our data through filings on 89bio, Inc. shares, published by SEC (Form 4). In total, 29 filings cover trades dated from 5 February 2022 to 30 October 2025.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The latest filing, published on 30 October 2025, reports a share grant in 89bio, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 29 declarations